AUTHOR AND EDITOR INFORMATION

Section 1 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

INTRODUCTION

Section 2 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Background

Molluscum contagiosum virus (MCV) causes a benign viral infection that is largely (if not exclusively) a disease of humans.

MCV causes characteristic skin lesions consisting of single or, more often, multiple, rounded, dome-shaped, pink, waxy papules 2-5 mm (rarely up to 1 cm) in diameter. The papules are umbilicated and contain a caseous plug. MCV is an unclassified member of the Poxviridae family, with features intermediately between the Orthopoxvirus and Parapoxvirus genera. It cannot be grown in tissue culture or eggs. It has been grown in human foreskin grafted to athymic mice but has not been transmitted to other laboratory animals.

By restrictive endonuclease analysis of the genomes of isolates, the following 4 types have been identified: MCV I, II, III, and IV. In one study of 147 patients, MCV I caused 96.6% of infections, and MCV II caused 3.4%; however, no relationship was observed between virus type and lesional morphology or anatomical distribution.¹ MCV III and IV are rare. In patients with human immunodeficiency virus (HIV) infection, MCV II causes most infections (60%).

Bateman first described the disease in 1817, and Paterson demonstrated its infectious nature in 1841. In 1905, Juliusburg proved its viral nature. Infection follows contact with infected persons or contaminated objects, but the extent of epidermal injury necessary is unknown. Lesions may spread by autoinoculation. MCV may be inoculated along a line of minor skin trauma, resulting in lesions arranged in a linear pattern. This process, termed autoinoculation, is different from the Koebner phenomenon, which is also called an isomorphic response. In the Koebner phenomenon, new lesions develop along a line of trauma and the etiology of the underlying condition is unknown. Psoriasis and lichen planus are examples of skin conditions that commonly koebnerize.

Methods of MCV transmission between patients have been reported with direct skin contact by children sharing a bath and by athletes sharing gymnasium equipment and benches. An association between school swimming pool use and MC infection is also reported.

Three distinct disease patterns are observed in 3 different patient populations: children, adults who are immunocompetent, and patients who are immunocompromised (children or adults). The prognosis and therapy are different for each situation.

MC is most common in children who become infected through direct skin-to-skin contact or indirect skin contact with fomites, such as bath towels, sponges, and gymnasium equipment. Lesions typically occur on the chest, arms, trunk, legs, and face. Hundreds of lesions may develop in intertriginous areas, such as the axillae and intercrural region. Lesions may rarely occur on the mucous membranes of the lip, tongue, and buccal mucosa. The palms are spared. Patients with atopic dermatitis may develop large numbers of lesions.

In adults, MC most commonly is a sexually transmitted disease (STD). Healthy adults tend to have few lesions, which are limited to the perineum, genitalia, lower abdomen, or buttocks. MC in healthy children and adults is usually a self-limited disease.

Widespread, persistent, and atypical MC may occur in patients who are significantly immunocompromised or have acquired immunodeficiency syndrome (AIDS) with low CD4 T-lymphocyte counts. MC may be the presenting complaint in patients with AIDS. MCV infection in immunocompromised patients may be particularly resistant to therapy. Other opportunistic infections in these patients may closely resemble MC.

Pathophysiology

The virus replicates in the cytoplasm of epithelial cells, producing cytoplasmic inclusions and enlargement of infected cells. This virus only infects the epidermis. Infection follows contact with infected persons or contaminated objects, but the extent of necessary epidermal injury is unknown. The initial infection seems to occur in the basal layer, and the incubation period is usually 2-7 weeks. This is suggested by the fact that, although viral particles are noted in the basal layer, viral DNA replication and the formation of new viral particles do not occur until the spindle and granular layers of the epidermis are involved. Infection may be accompanied by a latent period of as long as 6 months.

Following infection, cellular proliferation produces lobulated epidermal growths that compress epidermal papillae, while fibrous septa between the lobules produce pear-shaped clumps with the apex upwards. The basal layer remains intact. Cells at the core of the lesion show the greatest distortion and are ultimately destroyed, resulting in large hyaline bodies (ie, molluscum bodies, Henderson-Paterson bodies) containing cytoplasmic masses of virus material. These bodies are present in large numbers and appear as a white depression at the center of fully developed lesions. Occasionally, the lesions can progress beyond local cellular proliferation and become inflamed with attendant edema, increased vascularity, and infiltration by neutrophils, lymphocytes, and monocytes.

As with other poxviruses, MCV does not appear to develop latency but evades the immune system through the production of virus-specific proteins. Cell-mediated immunity is most important in modulating and controlling the infection. Children and patients with HIV infection generally have more widespread lesions. Prevalence of MCV in patients with HIV may be as high as 5-18%, and the severity of infection is inversely related to the CD4 T-lymphocyte count. More extensive and resistant infections also are noted in patients receiving prednisone and methotrexate.

The virus is not strongly immunogenic, as it infrequently induces antibody formation. Specific antibodies have been found in approximately 80% of patients and in about 15% of control subjects. A role for humoral immunity in regression of lesions is not established. Reinfection is common.

Frequency

United States

MC is a common infection throughout the United States and accounts for approximately 1% of all skin disorders diagnosed. Data reported from 1969-1983 by the National Disease and Therapeutic Index Survey show an increasing number of patient visits. The prevalence rate in patients with HIV is reported to be 5-18%, and, if the CD4 cell counts are less than 100 cells/μL, the prevalence of MC is reported to be as high as 33%.

International

The virus occurs throughout the world, and its incidence in most areas is not reliably known. It is more prevalent in tropical areas. In Mali, MC is among the most frequent dermatoses in children, with an incidence of 3.6%.² In Australia, an overall seropositivity rate of 23% is reported.³ The lowest antibody prevalence was in children aged 6 months to 2 years (3%), and seropositivity increased with age to reach 39% in persons aged 50 years or older.

Childhood MC is common in Papua New Guinea, Fiji, and certain parts of Africa. During a regional outbreak in East Africa, it was estimated that 17% of the village population and as many as 52% of children older than 2 years developed lesions. Epidemiological studies suggest that transmission may be related to poor hygiene and climatic factors such as warmth and humidity. In England and Wales at STD clinics, incidence increased approximately 10-fold from 1971-1978.

Mortality/Morbidity

• MC is generally a benign and self-limited infection.
• For the most part, morbidity is caused by temporary adverse cosmetic results. Morbidity is higher in immunocompromised patients because they tend to have more lesions and more widespread infection. Most lesions resolve with no permanent residual skin defect; however, occasional lesions may produce a slightly depressed scar. This may represent deeper skin damage in lesions that were particularly inflammatory or secondarily infected. Involvement of the margin of the eyelids may produce keratoconjunctivitis.

Race

• During a US longitudinal study performed from 1977-1981, 2-4 times as many cases were found in whites than in persons of other races.⁴ Whether the noted difference was secondary to differences in access to medical care, other socioeconomic factors, or genetic predisposition is unclear.

Sex

• Several studies have shown that males are affected more commonly than females.
• In STD clinics in England and Wales, slightly more than twice as many men are diagnosed as women.

Age

• The disease is rare in children younger than 1 year, perhaps because of maternally transmitted immunity and a long incubation period; otherwise, incidence seems to reflect exposure to others. The greatest incidence is in children younger than 5 years and young adults. The peak among the pediatric age group correlates with casual contact, whereas the peak in young adults correlates with sexual contact.
• Spread of the virus among households is common in warm-climate countries where children are lightly dressed and in close contact with one another and where personal hygiene may be poor. The age of peak incidence is reported to be 2-3 years in Fiji and 1-4 years in the Congo (formerly Zaire). In New Guinea, the annual infection rate for children younger than 10 years was 6%. In cooler climates, spread within households is less common, and infection is more common at a later age. Use of school swimming pools is correlated with childhood infections, with a peak incidence in children aged 10-12 years in Scotland and 8 years in Japan. Prevalence appears to be increasing in all age groups.

CLINICAL

Section 3 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

History

• Molluscum contagiosum (MC) is usually asymptomatic; however, individual lesions may be tender or pruritic.
• In general, the patient does not experience systemic symptoms, such as fever, nausea, or malaise.
• The patient may recall contact with an infected sexual partner, family member, or other person.
• Patients who report having multiple sexual partners or unprotected sex have an increased risk of infection.
• Contact may be reported in children sharing a bath or in athletes sharing gymnasium equipment and benches.
• If the patient has skin conditions that disrupt the epidermal layer, molluscum tends to spread more rapidly.
• • The patient may notice new lesions developing along a scratch in areas of involved skin.
  • Patients with atopic dermatitis may have more extensive disease. Patients with atopic dermatitis may have a positive family history of atopy (eg, eczema, asthma, hayfever).
• Duration of the individual lesion and of the attack is variable. Although most cases resolve without therapy within 6-9 months, some persist for 3-4 years. Individual lesions seldom persist more than 2 months.
• Patients with HIV or those receiving prednisone, methotrexate, or other immunosuppressive medications may have more extensive and resistant infections.

Physical

• Lesions are discrete, nontender, flesh-colored, dome-shaped papules that show a central umbilication (more apparent when lesion is frosted with liquid nitrogen).
• Lesions are usually 2-6 mm in diameter (rarely up to 3 cm) and may be present in groups or widely disseminated. Immunocompetent children and adults usually have fewer than 20 lesions. Larger lesions may have several distinct clumps of molluscum bodies. Beneath the umbilicated center is a white curdlike core that contains molluscum bodies. Some lesions become confluent to form a plaque (agminate form).
• Lesions may be located anywhere; however, a predilection for the face, trunk, and extremities is observed in children and a predilection for the groin and genitalia is observed in adults. Lesions are seldom found on palms and are rarely documented on the soles, oral mucosa, and conjunctiva.
• In sexually active individuals, the lesions may be confined to the penis, pubis, and inner thighs.
• Distribution is influenced by the mode of infection, type of clothing worn, and climate.
• Hundreds of lesions may develop in intertriginous areas, such as the axillae and intercrural region.
• Patients with atopic dermatitis occasionally develop large numbers of lesions, which are confined to areas of lichenified skin.
• Widespread and persistent MC may occur in patients with AIDS and may be the presenting complaint.
• Approximately 10% of patients develop eczema around the lesions. This is attributed to toxic substances produced by the virus or to a hypersensitivity reaction to the virus.
• Eczema that is associated with molluscum lesions subsides spontaneously following removal.
• Lesions may spontaneously resolve or following minor trauma. Inflammatory changes result in suppuration, crusting, and eventual resolution of the lesion. This inflammatory stage does not usually represent secondary infection and seldom requires antibiotic therapy.
• MC may be randomly associated with other lesions, such as epidermal cysts, nevocellular nevi, sebaceous hyperplasias, and Kaposi sarcoma. Pseudocystic MC, giant MC, and MC associated with other lesions are responsible for frequent clinical misdiagnosis.
• Disfiguring lesions may occur in patients with the following conditions:
• • AIDS: Facial and perioral MC are most commonly observed as a manifestation of HIV infection, particularly in homosexual men with HIV. At the time of MC diagnosis, the CD4 count is low.
  • Sarcoidosis
  • Lymphocytic leukemia
  • Congenital immunodeficiency
  • Selective immunoglobulin M (IgM) deficiency
  • Thymoma
  • Treatment with prednisone and methotrexate
  • Disseminated malignancy
  • Refractory atopic dermatitis
  • Immunocompromise: Lesions are especially common and extensive on the face and neck.

Causes

• MC is a viral disease caused by a DNA poxvirus and is largely, if not exclusively, a disease of humans. It is an unclassified member of the Poxviridae family (ie, poxviruses), with features intermediately between the Orthopoxvirus and Parapoxvirus groups. The poxviruses are a large group of viruses with a high molecular weight. They are the largest animal viruses, only slightly smaller than the smallest bacteria, and are just visible using light microscopy. They are complex DNA viruses that replicate in the cytoplasm and are especially adapted to epidermal cells. They cannot be grown in tissue culture or eggs. MCV has been grown in human foreskin grafted to athymic mice but not in other laboratory animals.
• Humans are the host for the following 3 types of MCV:
• • Orthopoxvirus: This resembles variola (smallpox) and vaccinia, which are ovoid (300 X 250 nm).
  • Parapoxvirus: These are orf and milkers nodule viruses, which are cylindrical (260 X 160 nm).
  • Unclassified (with features that are intermediately between the orthopox and parapox groups): These are intermediate in structure (275 X 200 nm). They include MCV and tanapox.
• In 1996, the primary structure and coding capacity of MCV was determined by Senkevich et al.⁵ Analysis of the MCV genome has revealed that it encodes approximately 182 proteins, 105 of which have direct counterparts in orthopoxviruses.
• Restriction endonuclease analysis of the genomes has identified 4 types.
• • MCV I and MCV II have genomes of 185 kilobases (kb) and 195 kb, respectively.
  • MCV III and IV are very rare.
  • No relationship between virus type and lesional morphology or anatomical distribution is known.
  • MCV encodes an antioxidant protein (MC066L), selenoprotein, which functions as a scavenger of reactive oxygen metabolites and protects cells from UV or peroxide damage. The particular role of this protein is not known.
• In one study, type I caused 96.6% and type II caused 3.4% of infections in 147 patients, but no relationship was observed between virus type and lesional morphology or anatomical distribution.¹

DIFFERENTIALS

Section 4 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Other Problems to be Considered

Basal cell carcinoma
Keratoacanthoma
Verruca vulgaris (warts)
Eccrine poroma
Epidermal cyst
Foreign body granuloma

Perforating disorders (all very rare in children)

Acquired reactive perforating dermatosis of renal failure
Kyrle disease
Perforating serpiginous elastoma
Perforating folliculitis
Verrucous perforating collagenoma
Perforating granuloma annulare

In patients with AIDS

Cutaneous cryptococcus (Cutaneous cryptococcus presents as molluscumlike eruptions and are often very dramatic on the face. The patient may have few or no other symptoms associated with cryptococcal meningitis.)
Cutaneous coccidioidomycosis
Cutaneous histoplasmosis
Cutaneous aspergillosis

WORKUP

Section 5 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Lab Studies

• In most instances, diagnosis is easily established because of distinctive central umbilication of the dome-shaped lesion. Pseudocystic molluscum contagiosum (MC), giant MC, and MC associated with other lesions may be more difficult to diagnose clinically.
• If diagnosis is uncertain, lesions may be biopsied. Characteristic intracytoplasmic inclusion bodies (molluscum bodies or Henderson-Patterson bodies) are seen on histological examination findings.
• Express the pasty core of a lesion by crushing between 2 microscope slides and stain to reveal the particulate virions, which are present in abundance. Firm compression between the slides is required to release the virions with the stain in place. The use of crystal violet, safranin, and ammonium oxalate in 10% ethanol (Sedi-Stain; Clay-Adams, Parsippany, NJ); Papanicolaou test; or Wright, Giemsa, or Gram stains can reveal the virions that make up the molluscum bodies.
• Measure serum antibodies by complement fixation, tissue culture neutralization, fluorescent antibody, and gel agar diffusion techniques; however, they are not well standardized and are seldom used except in research protocols.
• Polymerase chain reaction can be used to detect and categorize MCV in skin lesions.
• MCV cannot be grown in tissue culture; however, Buller et al demonstrated MCV replication in an experimental system using human foreskin grafted to athymic mice.⁶
• Evaluate the patient for other STDs because sexually active patients may acquire other concomitant venereal diseases, such as syphilis and gonorrhea.
• Always consider testing for HIV infection in patients with facial lesions.

Histologic Findings

Lesions have a characteristic histopathology. In the fully developed lesion, a crater appears near the surface and gradually extends into lobules that contain hyalinized molluscum bodies (ie, Henderson-Paterson bodies), which can measure 35 mm in diameter. Molluscum bodies are membrane-bound sacks that contain numerous MC virions. Downward proliferation of the rete ridges with envelopment by the connective tissue forms the crater. Enlarged deep-purple keratinocytes develop above the basal cell layer of the epidermis. These enlarged keratinocytes contain viral particles, which increase in size as the cells progress upwards. Eventually, the bulk of the viral particles compress the nucleus to the side of the cell to form crescent-shaped nuclei. Intact lesions show little or no inflammatory changes.

Lesions with intradermal rupture of molluscum bodies show an intense dermal inflammatory infiltrate consisting of lymphocytes, histiocytes, and occasional multinucleated foreign body giant cells.

TREATMENT

Section 6 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical Care

• Before attempting any therapy, educate the patient or parents in-depth about the diagnosis, prognosis, risk of autoinoculation or infection of others, therapeutic options, and risks of therapy. More than one treatment session is frequently required. Providing this information at the first clinical visit is particularly important when treating benign lesions, such as molluscum contagiosum (MC) and common warts. A few extra minutes of explanation at this stage can prevent or mitigate numerous problems and questions during later visits. When lesions fail to respond to initial therapy, a temptation to be overzealous in treatment may occur. Patients and families are more understanding and less likely to demand aggressive therapy when reasonable goals and limitations of therapy are thoroughly discussed.
• In healthy patients, MC is generally self-limited and heals spontaneously after several months. Individual lesions are seldom present for more than 2 months. Although treatment is not required, it may help reduce autoinoculation or transmission to close contacts and improve clinical appearance.
• The most appropriate therapeutic approach largely depends on the clinical situation. In healthy children, a major goal is to limit discomfort, and benign neglect or minor direct lesional trauma is appropriate. In adults who are more motivated to have their lesions treated, cryotherapy or curettage of individual lesions is effective and well tolerated. In immunocompromised individuals, MC may be very extensive and difficult to treat. The goal may be to treat the most troublesome lesions only. In severe cases, these patients may warrant more aggressive therapy with lasers, imiquimod, antiviral therapy, or combinations of these. Of course, effective antiretroviral therapy in patients with AIDS makes therapy of MC much more effective.
• Controlled studies that compare treatments have not been performed, and all treatments have benefits and disadvantages. A review for the Cochrane Database in April 2006 examined the effects of several topical, systemic, and homeopathic interventions.⁷
• • Limited evidence demonstrated the efficacy of sodium nitrite coapplied with salicylic acid compared with salicylic acid alone.
  • No statistically significant differences were found for topical povidone iodine plus salicylic acid compared with povidone iodine alone or compared with salicylic acid alone.
  • Also, no statistically significant differences were found when potassium hydroxide was compared with placebo; systemic treatment with cimetidine versus placebo or systemic treatment with calcarea carbonica, a homeopathic drug, versus placebo.
  • Study limitations were numerous and may have led to important differences being missed.
  • None of the evaluated treatment options were associated with serious adverse effects.
  • The authors concluded no single intervention has been shown to be convincingly effective in treating MC.
• Hanna et al reported a prospective randomized trial that compared the efficacy and adverse effects of 4 recognized treatments of MC in children.⁸ They compared 4 treatments in 124 children. One group was treated with curettage, a second with cantharidin, a third with a combination of salicylic acid and lactic acid, and a fourth with imiquimod. Curettage was found to be the most efficacious treatment and had the lowest rate of side effects, but it must be performed with adequate anesthesia and is a time-consuming procedure. Cantharidin had moderate complications due to blisters and was slightly less effective. The topical keratolytic used was too irritating for children. Topical imiquimod was more effective than cantharidin but is expensive, and an optimum treatment schedule is yet to be reported.
• Therapeutic options can be divided into several broad categories, including benign neglect, direct lesional trauma, immune response stimulation, and antiviral therapy.
• • Benign neglect
  • • Leaving mollusca to spontaneously resolve is often reasonable, especially in young children for whom freezing or curettage may be painful and frightening. The dictum primum non nocere (first do no harm) has a special significance in children with minor self-limited conditions. Many physicians refuse to treat children with small numbers of mollusca.
    • Lesions on the eyelids and central face may be particularly distressing to parents and patients. When possible, treat lesions at other locations first, with the hope that the treatment may stimulate the facial lesions to spontaneously resolve. When facial lesions require treatment, the best option is to treat them frequently with minor physical trauma.
    • More aggressive therapy may be required in patients in whom the extent of disease is intolerable and in patients who are immunocompromised.
  • Direct lesional trauma
  • • Takematsu et al reported that disruption of the epidermal wall of molluscum bodies induces acute inflammatory changes by activation of the alternative complement pathway on exposure to the tissue fluids; furthermore, the molluscum bodies release proinflammatory cytokines and other neutrophil chemotactic factors upon decomposition.⁹ This supports the observation that minor trauma to molluscum lesions frequently produces an inflammatory response and resolution of the lesion. The molluscum bodies can be ruptured and a local inflammatory response created by various forms of physical trauma and caustic topical agents.
    • For information on physical trauma treatments, see Surgical Care.
    • Various caustic agents have been shown to be effective in treating MC. Tretinoin, salicylic acid, and potassium hydroxide (KOH) may be prescribed for application at home. Cantharidin, silver nitrate, trichloroacetic acid, and phenol should be applied in the office. Children may tolerate therapy with these agents better than curettage or cryotherapy. None of these caustic agents have been approved by the US Food and Drug Administration (FDA) for treatment of MC.
    • Tretinoin cream 0.1% or gel 0.025% is applied daily. Apply to a region of skin with scattered lesions. It may produce eczema and may increase the number of lesions through autoinoculation; however, a small amount of tretinoin may be applied to individual lesions with the rough end of a broken toothpick. Rotate the toothpick, gently abrading the lesion and increasing the inflammatory response produced by the tretinoin. Treat lesions every few days until significant inflammation or resolution occurs.
    • KOH is a strong alkali that has long been known to digest proteins, lipids, and most other epithelial debris of skin scrapings to identify fungal infections. Topical 10% KOH aqueous solution applied twice daily on each MC lesion until all lesions undergo inflammation and superficial ulceration may be effective in clearing MC in children.
    • Cantharidin is a chemovesicant that is highly effective in treating MC but has lost favor with some physicians because of concerns regarding its safety. However, if cantharidin is used properly, it is very effective, safe, and well tolerated by children. In a study by Silverberg et al, 300 patients were treated with cantharidin.¹⁰ Ninety percent of patients experienced compete clearing with an average of 2.1 visits. Blisters occurred at sites of application in 92% of patients. Temporary burning, pain, erythema, or pruritus was reported in 6-37% of patients. No major adverse effects were reported, and no patients experienced secondary bacterial infection. A total of 95% of parents reported they would proceed with cantharidin therapy again.
    • Cantharidin is not approved by the FDA for treatment of any condition; however, it has been used safely and effectively by dermatologists for many years. It is listed as acceptable therapy in the American Academy of Dermatology treatment guidelines for warts; however, because it has never been approved by the FDA for use in humans, it is no longer marketed as medical therapy in the United States. Cantharidin crystals and diluent can be purchased in the United States, and many dermatologists continue to use it. Cantharidin solution for the treatment of warts and molluscum is available in Canada and many other countries.
    • Seventeen percent salicylic acid in collodion (Compound W, Freezone, Wart-Off, Occlusal) is commonly used in treating verruca vulgaris. In most patients, repeated application to individual MC lesions until an inflammatory response is generated is effective therapy.
  • Immune response stimulation
  • • Imiquimod cream, intralesional interferon alfa, and topical injections of streptococcal antigen have been shown to be effective in treating patients with resistant MC. The high cost of these products limits their use to more extensive or resistant infections. Imiquimod cream applied 3 times a week for 16 weeks is an option in severe cases. The dosing schedule and length of treatment require further evaluation.
    • Imiquimod is a novel topical immune response modifier, which is a potent inducer of interferons. Various treatment regimens have been effective in treating MC. In children and in some patients with AIDS-associated MC, 1% cream applied 3 times per day or 5% cream applied at every bedtime for 4 weeks appears to be effective treatment.
  • Antiviral therapy
  • • In immunocompromised patients, improvement of lesions has been observed in individual patients treated with ritonavir, cidofovir (intravenous and topical), and zidovudine.
    • Not surprisingly, patients with AIDS and severe MC improve with effective antiretroviral therapy.

Surgical Care

• Varying degrees of physical trauma to individual lesions are used and are frequently quite successful. Physical trauma to individual MC lesions can be performed with cryotherapy, lasers, curettage, expression of the central core with tweezers, rupture of the central core with a needle or a toothpick, electrodesiccation, or shave removal.
• Instruct the parents to tease out the firm, white core at the center of lesions using a clean needle or a toothpick. The process of irritating the lesion usually causes it to inflame and resolve within 1-2 weeks. This safe and easy approach can be performed by the patient's parent, limiting the need for follow-up visits.
• In an office setting, curettage of individual lesions is easy and very effective. With a sharp curette and a quick firm motion, small individual lesions can be removed completely, with little or no bleeding. With practice and a sharp curette, the provider may perform this procedure with little or no discomfort. Older children, adolescents, and adults usually tolerate this procedure better.
• Other simple mechanical methods such as expression of the contents in the papule by squeezing it with forceps held parallel to the skin surface, or shaving off the lesions with a sharp scalpel are effective.
• Lesions may also be treated with light electrodesiccation. At very low voltage settings, anesthesia may not be required.
• Cryotherapy is the first-line treatment for many physicians, particularly in adolescents and adults. A brief freeze, which causes icing of the lesion and a thin rim of surrounding skin, is usually adequate. Treatment is repeated at intervals of 2-3 weeks until all lesions resolve. Achieve accurate spray of liquid nitrogen by using a disposable ear speculum. The small end is placed against the skin and liquid nitrogen is sprayed into the funnel created. Lesions also may be treated with cotton tip applicators chilled in liquid nitrogen and held against the lesion until a small amount of frosting occurs. Cryotherapy is painful and the smoke that rises off the cold applicator or the noise of the liquid nitrogen sprayer may be quite frightening to younger children.
• Pulsed dye laser (PDL) therapy has been shown to be more than 95% successful in treating individual lesions after one treatment. PDL treatment of MC has been used successfully in patients with AIDS. A significant reduction in the number of MC lesions following a single treatment with the PDL can be attained. Treated areas may remain disease-free for months. Although cost and availability are major limiting factors for routine use, it may be considered for treatment of extensive or resistant lesions. It may also be valuable in immunocompromised individuals with extensive disease.
• Treatment of MC in patients with AIDS remains a challenge. The combination of 2 or more therapeutic modalities, such as carbon dioxide laser, PDL, and trichloroacetic acid, can be of much help to improve the quality of life of these patients.
• The discomfort of curettage or other mechanical removal may be reduced, as follows:
• • Lesions may be sprayed with ethyl chloride until frosting has occurred and scraped away with a curette.
  • The application of local anesthetic cream, EMLA (a eutectic mixture of 5% lignocaine and prilocaine) or equivalent, may permit painless treatment. The cream is best applied under occlusion 1-2 hours before the planned procedure.

Activity

• Instruct the patient to avoid activities or sports involving physical contact between infected areas of skin and exposed skin of other participants.

MEDICATION

Section 7 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Molluscum contagiosum (MC) usually resolves within months in people with a normal immune system. Many treatments have been promoted for MC. The common goal of most treatment methods is the destruction of lesions and the development of a localized inflammatory reaction. Extensive controlled studies have not been performed and all treatments have advantages and disadvantages.

The ideal treatment for MC depends on many factors including patient/parent preference, fear, cost, travel time to the office, number and distribution of lesions, associated medical conditions, and immune status. Before attempting any therapy, educate the patient and parents in depth about the diagnosis, prognosis, risk of autoinoculation and infection of others, therapeutic options, and risks of therapy. Providing this background and prognosis at the first clinic visit is important in minimizing disappointment associated with "treatment failure."

Drug Category: Cytotoxic and caustic agents

These agents inhibit cell growth and destroy infected cells. They are applied directly to lesions. To decrease discomfort, treat a small number of lesions at each visit.

Drug Category: Immune response modifiers, topical

These agents induce cytokines, including interferon. They are typically reserved for use in patients with MC that is refractory to cryotherapy or tretinoin.

Drug Category: Antiviral drugs

Presumably, antiviral drugs may interfere with the ability of the MCV to replicate. Because of expense and adverse effect potential, only consider these products in immunocompromised patients.

FOLLOW-UP

Section 8 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Further Outpatient Care

• Retreatment is often necessary.

Deterrence/Prevention

• Most cases in adolescents and adults are secondary to sexual contact. Abstinence and careful selection of sexual partners are important. Whether condoms are effective in preventing spread is unclear.
• Good personal hygiene is important in limiting transmission.
• Autoinoculation may result from trauma, such as shaving or manipulation of lesions by the patient.

Complications

• Complications include irritation, inflammation, and secondary infections.
• Lesions on eyelids may be associated with follicular or papillary conjunctivitis.
• Bacterial superinfection may occur but is seldom of clinical significance.
• Autoinoculation is possible.
• Infection may be transmitted to others.
• Immunocompromised individuals may have extensive cutaneous infections.

Prognosis

• Prognosis is generally excellent because the disease is usually benign and self-limited.
• In healthy patients, treatments are usually effective.
• Lesions can be disfiguring and produce anxiety in the patient, family, and daycare facility or school.
• Recurrences occur in as many as 35% of patients after initial clearing. The significance of these recurrences is unknown. They may represent reinfection, exacerbation of ongoing disease, or new lesions arising after a prolonged latent period.
• The disease often becomes generalized in patients who are infected with HIV or are otherwise immunocompromised. A direct correlation has been found between increasing severity of the disease and lower CD4 counts.

Patient Education

• Stress the benign nature of this ubiquitous disease to the patient and parents.
• Limiting physical contact with infected areas of skin and good handwashing may reduce transmission.
• Instruct the patient to avoid scratching, which may result in autoinoculation.
• Keeping children out of school is not necessary; however, discourage physical contact and sharing of clothes and towels. In smaller children in whom physical contact is more difficult to prevent, keeping infected areas covered with clothing is reasonable. Cover exposed lesions with tape or an adhesive bandage. Infection of other children cannot be completely prevented. Because the disease is extremely common and of very little clinical significance, the decision to limit infected children from daycare centers must be approached on a case-by-case basis.
• In adolescent and adult patient populations, this disease is usually sexually transmitted. Encourage safe sex and abstinence; however, whether condoms and other barrier methods provide adequate protection against transmission is unclear.
• Emphasize that not all STDs are as benign as molluscum contagiosum virus (MCV) (eg, herpes simplex, gonorrhea, chlamydia, HIV). Stress adherence to abstinence until lesions resolve. In the patient with multiple sexual partners or other risk factors, HIV testing is strongly recommended.
• Note that not all cases in adults are sexually transmitted. This diagnosis can cause significant relationship stress.
• For excellent patient education resources, visit eMedicine's Procedures Center and Skin, Hair, and Nails Center. Also, see eMedicine's patient education articles Molluscum Contagiosum, Birth Control Overview, and Birth Control FAQs.

MISCELLANEOUS

Section 9 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical/Legal Pitfalls

• Infection of children through sexual abuse is possible; however, to a greater extent than warts, molluscum contagiosum virus (MCV) is quite common on the genital, perineal, and surrounding skin of children. Regard abuse as unlikely, unless other suspicious features are present.
• Histological or microscopic confirmation of MC is indicated in patients who are immunocompromised because several life-threatening opportunistic infections may clinically mimic MC.

MULTIMEDIA

Section 10 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Media file 1:  Note the central umbilication in these classic lesions of molluscum contagiosum.
	View Full Size Image
Media type:  Photo

Media file 2:  Approximately 10% of patients develop eczema around lesions. Eczema associated with molluscum lesions spontaneously subsides following removal.
	View Full Size Image
Media type:  Photo

Media file 3:  Molluscum contagiosum on the shaft of the penis. Molluscum contagiosum in the genital region of adults is most commonly acquired as a sexually transmitted disease.
	View Full Size Image
Media type:  Photo

Media file 4:  Larger lesions may have several clumps of molluscum bodies rather than the more common single central umbilication. This may make them difficult to recognize as molluscum contagiosum.
	View Full Size Image
Media type:  Photo

Media file 5:  Molluscum lesions may become quite numerous in intertriginous areas. This child has autoinoculated lesions to both inner thighs.
	View Full Size Image
Media type:  Photo

Media file 6:  After trauma, or spontaneously after several months, inflammatory changes result in suppuration, crusting and eventual resolution of the lesion. This inflammatory stage does not usually represent secondary infection and seldom requires antibiotic therapy.
	View Full Size Image
Media type:  Photo

Media file 7:  Lesions of molluscum contagiosum have a characteristic histopathology. Lobules containing hyalinized molluscum bodies, also known as Henderson-Paterson bodies, are diagnostic.
	View Full Size Image
Media type:  Photo

Media file 8:  This lesion of cutaneous coccidioidomycosis could be included among the differential diagnoses of molluscum contagiosum.
	View Full Size Image
Media type:  Photo

Media file 9:  This keratoacanthoma could be included among the differential diagnoses of molluscum contagiosum.
	View Full Size Image
Media type:  Photo

Media file 10:  Lesions on the upper eyelid of a 3-year-old child.
	View Full Size Image
Media type:  Photo

Media file 11:  In a patient who had preexisting molluscum contagiosum, the virus was inoculated along a line of minor skin trauma, resulting in the development of the 3 new lesions.
	View Full Size Image
Media type:  Photo

Media file 12:  Molluscum contagiosum on the right axilla.
	View Full Size Image
Media type:  Photo

REFERENCES

Section 11 of 11

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

1. Scholz J, Rosen-Wolff A, Bugert J, et al. Epidemiology of molluscum contagiosum using genetic analysis of the viral DNA. J Med Virol. Feb 1989;27(2):87-90. [Medline].
2. Mahe A, Prual A, Konate M, Bobin P. Skin diseases of children in Mali: a public health problem. Trans R Soc Trop Med Hyg. Sep-Oct 1995;89(5):467-70. [Medline].
3. Konya J, Thompson CH. Molluscum contagiosum virus: antibody responses in persons with clinical lesions and seroepidemiology in a representative Australian population. J Infect Dis. Mar 1999;179(3):701-4. [Medline].
4. Becker TM, Blount JH, Douglas J, Judson FN. Trends in molluscum contagiosum in the United States, 1966-1983. Sex Transm Dis. Apr-Jun 1986;13(2):88-92. [Medline].
5. Senkevich TG, Koonin EV, Bugert JJ, et al. The genome of molluscum contagiosum virus: analysis and comparison with other poxviruses. Virology. Jun 23 1997;233(1):19-42. [Medline].
6. Buller RM, Burnett J, Chen W, Kreider J. Replication of molluscum contagiosum virus. Virology. Nov 10 1995;213(2):655-9. [Medline].
7. van der Wouden JC, Menke J, Gajadin S, Koning S, Tasche MJ, van Suijlekom-Smit LW. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2006;(2):CD004767. [Medline].
8. Hanna D, Hatami A, Powell J, et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatr Dermatol. Nov-Dec 2006;23(6):574-9. [Medline].
9. Takematsu H, Tagami H. Proinflammatory properties of molluscum bodies. Arch Dermatol Res. 1994;287(1):102-6. [Medline].
10. Silverberg NB, Sidbury R, Mancini AJ. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. J Am Acad Dermatol. Sep 2000;43(3):503-7. [Medline].
11. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol Online J. Feb 2001;7(1):20. [Medline].
12. Bardenstein DS, Elmets C. Hyperfocal cryotherapy of multiple Molluscum contagiosum lesions in patients with the acquired immune deficiency syndrome. Ophthalmology. Jul 1995;102(7):1031-4. [Medline].
13. Bargman H. Is genital molluscum contagiosum a cutaneous manifestation of sexual abuse in children?. J Am Acad Dermatol. May 1986;14(5 Pt 1):847-9. [Medline].
14. Bayerl C, Feller G, Goerdt S. Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol. Nov 2003;149 Suppl 66:25-9. [Medline].
15. Betlloch I, Pinazo I, Mestre F, et al. Molluscum contagiosum in human immunodeficiency virus infection: response to zidovudine. Int J Dermatol. Jun 1989;28(5):351-2. [Medline].
16. Braue A, Ross G, Varigos G, Kelly H. Epidemiology and impact of childhood molluscum contagiosum: a case series and critical review of the literature. Pediatr Dermatol. Jul-Aug 2005;22(4):287-94. [Medline].
17. Brown CW Jr, O'Donoghue M, Moore J, Tharp M. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod. Cutis. Jun 2000;65(6):363-6. [Medline].
18. Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol. Oct 1999;135(10):1167-9. [Medline].
19. Bugert JJ, Darai G. Recent advances in molluscum contagiosum virus research. Arch Virol Suppl. 1997;13:35-47. [Medline].
20. Bugert JJ, Lohmuller C, Darai G. Characterization of early gene transcripts of molluscum contagiosum virus. Virology. Apr 25 1999;257(1):119-29. [Medline].
21. Bugert JJ, Melquiot NV, Darai G. Mapping of mRNA transcripts in the genome of molluscum contagiosum virus: transcriptional analysis of the viral slam gene family. Virus Genes. Oct 2000;21(3):189-92. [Medline].
22. Buntin DM, Roser T, Lesher JL Jr, et al. Sexually transmitted diseases: viruses and ectoparasites. Committee on Sexually Transmitted Diseases of the American Academy of Dermatology. J Am Acad Dermatol. Sep 1991;25(3):527-34. [Medline].
23. Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J Eur Acad Dermatol Venereol. Nov 2000;14(6):484-8. [Medline].
24. Calista D, Boschini A, Landi G. Resolution of disseminated molluscum contagiosum with Highly Active Anti-Retroviral Therapy (HAART) in patients with AIDS. Eur J Dermatol. Apr-May 1999;9(3):211-3. [Medline].
25. Castilla MT, Sanzo JM, Fuentes S. Molluscum contagiosum in children and its relationship to attendance at swimming-pools: an epidemiological study. Dermatology. 1995;191(2):165. [Medline].
26. Cattelan AM, Sasset L, Corti L, et al. A complete remission of recalcitrant molluscum contagiosum in an AIDS patient following highly active antiretroviral therapy (HAART). J Infect. Jan 1999;38(1):58-60. [Medline].
27. Choong KY, Roberts LJ. Molluscum contagiosum, swimming and bathing: a clinical analysis. Australas J Dermatol. May 1999;40(2):89-92. [Medline].
28. Clinical Effectiveness Group. National guideline for the management of molluscum contagiosum. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect. Aug 1999;75 Suppl 1:S80-1. [Medline].
29. Cribier B, Scrivener Y, Grosshans E. Molluscum contagiosum: histologic patterns and associated lesions. A study of 578 cases. Am J Dermatopathol. Apr 2001;23(2):99-103. [Medline].
30. Cronin TA Jr, Resnik BI, Elgart G. Recalcitrant giant molluscum contagiosum in a patient with AIDS. J Am Acad Dermatol. Aug 1996;35(2 Pt 1):266-7. [Medline].
31. Czelusta A, Yen-Moore A, Van der Straten M, et al. An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol. Sep 2000;43(3):409-32; quiz 433-6. [Medline].
32. Dave S, Thappa DM, Karthikeyan K. Disseminated and disfiguring molluscum contagiosum in a child. Pediatr Dermatol. Sep-Oct 2003;20(5):436-9. [Medline].
33. Davies EG, Thrasher A, Lacey K, Harper J. Topical cidofovir for severe molluscum contagiosum. Lancet. Jun 12 1999;353(9169):2042. [Medline].
34. Dohil M, Prendiville JS. Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients. Pediatr Dermatol. Jul-Aug 1996;13(4):310-2. [Medline].
35. Epstein E. Cantharidin treatment of molluscum contagiosum. Acta Derm Venereol. 1989;69(1):91-2. [Medline].
36. Epstein E. Treatment of molluscum contagiosum with griseofulvin. Schoch Letter. 1989;39:17.
37. Garrett SJ, Robinson JK, Roenigk HH Jr. Trichloroacetic acid peel of molluscum contagiosum in immunocompromised patients. J Dermatol Surg